News & Updates

Retifanlimab plus chemo improves survival in metastatic NSCLC
Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025 byStephen Padilla

The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.

Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025